Monitor CRIS stock price closely, any sustained dip below $1 could trigger a delist determination letter with no cure period. The one-year monitor period means the company must maintain compliance continuously; a single violation escalates directly to a hearing. Traders should watch for any reverse split announcements or capital raises aimed at supporting the bid price.
CRIS drugs
CRIS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 31 $5.02entry
- T+1 · 4mo ago +2.59%α +1.17% · $5.15
- T+5 · 3mo ago −19.92%α −23.43% · $4.02
- T+20 · 3mo ago −70.32%α −73.31% · $1.49
- T+60 · 22d ago −92.48%α −94.94% · $0.3773
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Curis Inc. received Nasdaq notice confirming it has regained compliance with the Bid Price Rule (Rule 5550(a)(2)) and is in full compliance with the Hearings Panel terms. However, the company is now subject to a one-year Discretionary Panel Monitor with strict conditions: any future deficiency will trigger a delist determination letter with no opportunity to submit a compliance plan or request additional time. While this avoids immediate delisting, the ongoing monitoring and low $10M market cap leave the stock vulnerable to any price dip.
Key Facts
- Regained compliance with Nasdaq Bid Price Rule 5550(a)(2) as of July 24, 2026
- Subject to a one-year Discretionary Panel Monitor per Listing Rule 5815(d)(4)(A)
- Any future deficiency will result in a Delist Determination Letter with no compliance plan or extension allowed
- Hearings Panel will consider compliance history in any appeal; no assurance of continued listing
Financial Impact
Avoids immediate delisting risk for a micro-cap ($10M market cap), failure to maintain compliance would likely trigger a delisting and severe liquidity loss
Risk Factors
- Failure to maintain minimum bid price or other listing standards during the monitor period
- Delisting would severely reduce institutional ownership and liquidity
- No ability to submit a compliance plan or request additional time for any deficiency
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001108205-26-000105 |
| Document: 0001108205-26-000105-index-headers.html | 0001108205-26-000105 |
| Document: 0001108205-26-000105-index.html | 0001108205-26-000105 |
| Document: 0001108205-26-000105.txt | 0001108205-26-000105 |
Track record
18 reports on CRIS
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +82.45% at T+60 after the May 22, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.4200 Now $0.4400 +4.76% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.6000 Now $0.4400 −26.67% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.5010 Now $0.4400 −12.18% settles Nov 17
- Nov 13, 20263d ago S-3 Bearish 7/10 Entry $0.6000 Now $0.4400 +26.67% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 4/10 Entry $0.4450 Now $0.4400 −1.12% settles Nov 17
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $0.4450 to $0.4358 Now $0.4400 +1.12% ▲ +2.07% +0.16% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $0.6530 to $0.5915 Now $0.4400 −32.62% ▼ −9.42% −10.74% vs SPY
- Nov 6, 202610d ago 8-K Bearish 7/10 Entry $0.6976 to $0.6530 Now $0.4400 +36.93% ▲ +6.39% +6.03% vs SPY
- Nov 2, 202614d ago DEF 14A Neutral 4/10 Entry $0.6610 to $0.7139 Now $0.4400 −33.43% ▲ +8.00% +7.70% vs SPY
- Oct 19, 202628d ago 8-K Bearish 6/10 Entry $0.3996 to $0.3920 Now $0.4400 −10.11% ▲ +1.90% +2.43% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers